Recommended pan-genotypic treatment protocols for people with hepatitis C virus (HCV) infection and compensated liver disease

Table 2. Recommended pan-genotypic treatment protocols for people with hepatitis C virus (HCV) infection and compensated liver disease, including people with HCV–HIV coinfection*

Regimen

HCV genotype

Pill burden

Treatment duration

No cirrhosis

Cirrhosis

First-line regimens for people who are treatment-naive

Sofosbuvir 400 mg, orally, daily

+

Velpatasvir 100 mg, orally, daily

1–6

1 pill daily

12 weeks

12 weeks†

Glecaprevir 300 mg, orally, daily

+

Pibrentasvir 120 mg, orally, daily

1–6

Once daily (3 pills)

8 weeks

12 weeks

Regimen for people who do not respond to first-line therapy due to virological failure

Sofosbuvir 400 mg, orally, daily

+

Velpatasvir 100 mg, orally, daily

+

Voxilaprevir 100 mg, orally, daily

1–6

1 pill daily

12 weeks

12 weeks

HIV = human immunodeficiency virus.

* Note that genotype-specific regimens for the treatment of people with HCV infection are still listed on the Pharmaceutical Benefits Scheme (see text).

† Addition of ribavirin may be considered for patients with genotype 3 HCV and compensated cirrhosis. Ribavirin dosing is weight-based; recommended dose is 1000 mg for people weighing < 75 kg and 1200 mg for people weighing ≥ 75 kg.